Management of Esophageal Varices
Introduction to Esophageal Varices Management
- Esophageal variceal bleeding is a serious complication of cirrhosis, and its management involves a combination of pharmacological, endoscopic, and radiological interventions, as recommended by the American Association for the Study of Liver Diseases (AASLD) 1, 2
Antibiotic Prophylaxis
- The British Society of Gastroenterology recommends antibiotic prophylaxis for 7 days, preferably with ciprofloxacin 1g/day or intravenous ceftriaxone 1g daily in advanced cirrhosis, to decrease bacteremia and spontaneous bacterial peritonitis and improve short-term survival by approximately 9.1% (95% CI 2.9-15.3; p<0.004) 3
- For patients with advanced cirrhosis (Child-Pugh B/C), intravenous ceftriaxone 1g daily for 7 days is recommended, particularly in settings with high prevalence of quinolone-resistant bacteria 4
- For patients with less severe cirrhosis (Child-Pugh A), oral ciprofloxacin 1g/day for 7 days is recommended 3
- The AASLD and other major guidelines consistently recommend a 7-day course of antibiotic prophylaxis, which has been established as the standard maximum length of treatment in multiple guidelines 3, 4
- Local antimicrobial susceptibility should be considered when selecting antibiotics 4
- Antibiotics should be initiated as soon as possible, ideally at presentation with suspected variceal bleeding 4
- The recommended antibiotic regimens are:
| Patient Population | Recommended Antibiotic Regimen |
|---|---|
| Advanced cirrhosis (Child-Pugh B/C) | IV ceftriaxone 1g daily for 7 days |
| Less severe cirrhosis (Child-Pugh A) | Oral norfloxacin 400 mg twice daily for 7 days or oral ciprofloxacin 500 mg twice daily for 7 days |
- Prophylactic antibiotics reduce bacterial infections (RR, 0.35; 95% CI, 0.26–0.47), decrease rebleeding rates (RR, 0.53; 95% CI, 0.38–0.74), and reduce bleeding-related mortality (RR, 0.79; 95% CI, 0.63–0.98), with a high strength of evidence supporting this fact 4, 2
Treatment Considerations
- Endoscopic variceal ligation (EVL) is the preferred method and should be performed within 12 hours of presentation, as recommended by the AASLD 2
- Rescue therapies for uncontrolled bleeding include TIPS (transjugular intrahepatic portosystemic shunt) and balloon tamponade as a temporary measure (maximum 24 hours) 2
- Vasoactive drug therapy, such as octreotide, somatostatin, or terlipressin, should be initiated immediately when variceal bleeding is suspected, with specific dosing regimens, as recommended by the American Gastroenterological Association 5
- Vasoactive drugs should be continued for 3-5 days, as recommended by KASL and AASLD 4, 2
- Beta-blockers should not be used in the acute setting of variceal bleeding as they decrease blood pressure and blunt physiologic heart rate increases, as recommended by the AASLD 2
- High-dose proton pump inhibitors are not specifically recommended for variceal bleeding, though they may help reduce the size of post-EVL ulcers, as stated by the American College of Gastroenterology 6
- Resuscitation with crystalloids is used to restore hemodynamic stability in patients with variceal bleeding, as recommended by the AASLD 1
Medication Considerations in Liver Disease
- Certain medications, such as aminoglycosides, vancomycin, rifampin, tetracycline, and erythromycin derivatives, carry a high risk of nephrotoxicity or hepatotoxicity in patients with liver disease, and should be used with caution, as recommended by AASLD 7
- The American Academy of Dermatology and the European Association for the Study of the Liver recommend ciprofloxacin, ceftriaxone, and rifaximin as the safest antibiotics to use in patients with chronic liver disease, with specific choices depending on infection type, severity, and presence of cirrhosis 8, 1
- For community-acquired infections, piperacillin-tazobactam or 3rd generation cephalosporin + oxacillin is recommended, as suggested by EASL 1
- For nosocomial infections, 3rd generation cephalosporin or meropenem + oxacillin/glycopeptides/daptomycin/linezolid is recommended, as suggested by EASL 1
- For community-acquired pneumonia, piperacillin-tazobactam or ceftriaxone + macrolide or levofloxacin/moxifloxacin is recommended, as suggested by EASL 1
- For nosocomial pneumonia, ceftazidime or meropenem + levofloxacin ± glycopeptides/linezolid is recommended, as suggested by EASL 1
- For uncomplicated community-acquired urinary tract infections, ciprofloxacin or co-trimoxazole is recommended, as suggested by EASL 1
- For urinary tract infections with sepsis, 3rd generation cephalosporin or piperacillin-tazobactam is recommended, as suggested by EASL 1
Prevention of Hepatic Encephalopathy
- Rifaximin is the first-line add-on therapy to lactulose for prevention of overt hepatic encephalopathy recurrence, as recommended by the Infectious Diseases Society of America 9
- Neomycin is an alternative choice but long-term use is limited by ototoxicity, nephrotoxicity, and neurotoxicity, as recommended by the Infectious Diseases Society of America 9
- Metronidazole is an alternative choice but long-term use is limited by neurotoxicity, as recommended by the Infectious Diseases Society of America 9